ATIM-22. PHASE I TRIAL OF DRUG RESISTANT IMMUNOTHERAPY: A FIRST-IN-CLASS COMBINATION OF MGMT-MODIFIEDγδ T CELLS AND TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME

INTRODUCTION: Alkylating agents such as Temozolomide (TMZ) significantly upregulate stress-induced NKG2D ligands targeted by innate immune effector cells. Genetic modification of γδT cells with an MGMT-expressing lentivector abrogates TMZ-induced lymphodepletion allowing simultaneous chemotherapy an...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Lamb, Lawrence, Markert, James, Yancey Gillespie, G, Beelen, Melissa, Langford, Catherine, Pereboeva, Larisa, Youngblood, Samantha, Nabors, Louis
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Adult Clinical Trials–Immunologic
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847234/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.021
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki